Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
28 hedge funds and large institutions have $11.3M invested in Marinus Pharmaceuticals, Inc in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
10% less funds holding
Funds holding: 31 → 28 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
79% less capital invested
Capital invested by funds: $52.8M → $11.3M (-$41.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.76M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$2.52M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$115K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$102K |
| 5 |
Goldman Sachs
New York
|
+$57.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$3.79M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.19M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.75M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.25M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$583K |
MRNS Hedge Fund Activity: Q2 2016 in Review
28 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2016, worth a combined $11.3M — down 79% from $52.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MRNS and 5 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Sphera Funds Management, adding an estimated $2.76M. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $3.79M sold.
- 28 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2016, down from 31 in Q1 2016.
- Funds reported $11.3M of Marinus Pharmaceuticals, Inc stock for Q2 2016, down 79% quarter-over-quarter.
- 5 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2016 and 8 closed out, a net change of -3 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2016 was Sphera Funds Management, an estimated $2.76M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2016 was New Leaf Venture Partners, an estimated $3.79M sold.
Based on aggregated 13F filings for Q2 2016.